

Application No. 09/915,549
November 28, 2005
Page 2 of 14

IN THE CLAIMS:

Claim 1 (canceled)

2. (currently amended) Dispersion ~~according to claim 1~~ which comprises:
an oily phase;

an aqueous phase, in the form of an oil-in-water emulsion or a water-in-oil emulsion; and

at least one active ingredient that is only slightly or with difficulty soluble in the oily phase and the aqueous phase, wherein the dispersion is free from toxicologically dangerous organic solvents and contains the active ingredient dissolved in a quantity that is greater than the quantity which results additively from its maximum solubility in the oily and the aqueous phase of the emulsion, wherein the active ingredient, in addition to the dissolved state, is partially present in highly dispersed solid crystalline form, resulting in a dispersion with a heterogeneously dispersed phase of oil drops and active ingredient crystals.

3. (original) Dispersion according to claim 2, wherein at least 90% of the active ingredient crystals present are smaller than 5 μm , volume distribution determined by laser diffractometry.

4. (original) Dispersion according to claim 2, wherein at least 95% of the active ingredient crystals present are smaller than 5 μm , volume distribution determined by laser diffractometry.

5. (original) Dispersion according to claim 2, wherein about 100% of the active ingredient crystals present are smaller than 5 μm , volume distribution determined by laser diffractometry.

Application No. 09/915,549
November 28, 2005
Page 3 of 14

6. (original) Dispersion according to claim 2, wherein at least 90% of the active ingredient crystals present are smaller than 3 μm , volume distribution determined by laser diffractometry.

7. (original) Dispersion according to claim 2, wherein at least 95% of the active ingredient crystals present are smaller than 3 μm , volume distribution determined by laser diffractometry.

8. (original) Dispersion according to claim 2, wherein about 100% of the active ingredient crystals present are smaller than 3 μm , volume distribution determined by laser diffractometry.

9. (original) Dispersion according to claim 2, wherein at least 90% of the active ingredient crystals present are smaller than 1 μm , volume distribution determined by laser diffractometry.

10.(original) Dispersion according to claim 2, wherein at least 95% of the active ingredient crystals present are smaller than 1 μm , volume distribution determined by laser diffractometry.

11.(original) Dispersion according to claim 2, wherein about 99% of the active ingredient crystals present are smaller than 1 μm , volume distribution determined by laser diffractometry.

12.(currently amended) Dispersion according to claim 42, wherein the dispersion comprises an oil-in-water emulsion and contains about 5 to about 99.5 wt.% of aqueous phase, based on the total weight of the dispersion.

Application No. 09/915,549
November 28, 2005
Page 4 of 14

13. (currently amended) Dispersion according to claim 42, wherein the dispersion comprises an oil-in-water emulsion and contains about 10 to about 95 wt.% of aqueous phase, based on the total weight of the dispersion.

14. (currently amended) Dispersion according to claim 42, wherein the dispersion comprises an oil-in-water emulsion and contains about 60 to about 95 wt.% of aqueous phase, based on the total weight of the dispersion.

15. (currently amended) Dispersion according to claim 42, wherein the dispersion comprises an oil-in-water emulsion and contains about 70 to about 95 wt.% of aqueous phase, based on the total weight of the dispersion.

16. (withdrawn) Dispersion according to claim 1, wherein the dispersion comprises an water-in-oil emulsion and contains about 5 to about 30 wt.% of aqueous phase, based on the total weight of the dispersion.

17. (withdrawn) Dispersion according to claim 1, wherein the dispersion comprises an water-in-oil emulsion and contains about 10 to about 25 wt.% of aqueous phase, based on the total weight of the dispersion.

18. (withdrawn) Dispersion according to claim 1, wherein the dispersion comprises an water-in-oil emulsion and contains about 10 to about 20 wt.% of aqueous phase, based on the total weight of the dispersion.

19. (currently amended) Dispersion according to claim 42, wherein the dispersion contains at least one selected from the group consisting of emulsifiers and stabilizers.

20. (original) Dispersion according to claim 19, wherein the dispersion contains less than 15 wt.% of emulsifiers and/or stabilizers, based on the total weight of the dispersion.

Application No. 09/915,549
November 28, 2005
Page 5 of 14

21. (original) Dispersion according to claim 19, wherein the dispersion contains less than 10 wt.% of emulsifiers and/or stabilizers, based on the total weight of the dispersion.

22. (original) Dispersion according to claim 19, wherein the dispersion contains less than 2 wt.% of emulsifiers and/or stabilizers, based on the total weight of the dispersion.

23. (original) Dispersion according to claim 19, wherein the dispersion contains from about 0.6 to about 1.2 wt.% of emulsifiers and/or stabilizers, based on the total weight of the dispersion.

24. (currently amended) Dispersion according to claim 42, wherein the dispersion comprises at least one emulsifier selected from the group consisting of egg lecithin, soya lecithin, phospholipids of egg or soya, sorbitan esters, sorbitane trioleate, polyethylene glycol sorbitan esters, polyoxyethylene sorbitane monooleate, sodium glycocholate, sodium lauryl sulphate, and mixtures thereof.

25. (currently amended) Dispersion according to claim 42, wherein the dispersion comprises at least one stabilizer selected from the group consisting of block co-polymers, poloxamers, Poloxamer 188 and 407, poloxamines, Poloxamine 908, polyvinyl pyrrolidone, polyvinyl alcohol, gelatine, polysaccharide, hyaluronic acid, chitosan, derivatives of chitosan, polyacryl acid, derivatives of polyacryl acid, polycarbophil, cellulose derivatives, methyl cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, sugar esters, saccharose monostearate, sodium citrate individually, and mixtures thereof.

26. (currently amended) Dispersion according to claim 42, wherein the dispersion comprises an oil-in- water emulsion and the oil phase used for the preparation of the dispersion comprises lipids which are solid at room temperature.

Application No. 09/915,549
November 28, 2005
Page 6 of 14

27. (currently amended) Dispersion according to claim 42, wherein the dispersion comprises an oil-in- water emulsion and the oil phase used for the preparation of the dispersion comprises lipids which are liquid at room temperature.

28. (currently amended) Dispersion according to claim 42, wherein the dispersion comprises an oil-in- water emulsion and the oil phase used for the preparation of the dispersion comprises a mixture of one or more lipids which are liquid at room temperature with one or more lipids which are solid at room temperature.

29. (original) Dispersion according to claim 28, wherein the mixture of liquid lipid : solid lipid varies from about 99:1 to about 1:99 parts by weight.

30. (original) Dispersion according to claim 29, wherein proportion of liquid lipid in mixture of lipids is at least 10 parts by weight.

31. (original) Dispersion according to claim 29, wherein proportion of liquid lipid in mixture of lipids is at least 30 parts by weight.

32. (original) Dispersion according to claim 29, wherein proportion of liquid lipid in mixture of lipids is at least 50 parts by weight.

33. (currently amended) Dispersion according to claim 42, wherein the oil phase comprises at least one individual lipid or mixtures thereof selected from the group consisting of natural and synthetic triglycerides, natural and synthetic monoglycerides, natural and synthetic diglycerides, self-emulsifying modified lipids, natural and synthetic waxes, fatty alcohols, esters of fatty alcohols, ethers of fatty alcohols, hard wax, Imwitor 900, glycerol trilaurate, glycerol myristate, glycerol palmitate glycerol stearate, glycerol behenat, waxes, cetyl palmitate, carnauba wax, white wax, hydrocarbons, and hard paraffin.

Application No. 09/915,549
November 28, 2005
Page 7 of 14

34. (currently amended) Dispersion according to claim 42, wherein the an oil phase comprises at least one selected from the group consisting of soya oil, safflower oil, long-chain triglycerides, medium-chain triglycerides, miglyols, fish oils, oils with an increased constituent of unsaturated fatty acids, and acetylated partial glycerides.

35. (currently amended) Dispersion according to claim 42, wherein the aqueous phase comprises water or mixtures of water with water-miscible organic liquids.

36. (currently amended) Dispersion according to claim 42, wherein the aqueous phase comprises water and at least one liquid polyethylene glycol.

37. (currently amended) Dispersion according to claim 42, wherein the aqueous phase contains at least one additive selected from the group consisting of electrolytes, non-electrolytes, glycerol, glucose, mannitol, xylite, gel forming agents, cellulose, and cellulose derivatives.

38. (currently amended) Dispersion according to claim 42, wherein the liquid and oily phase comprises at least one oil-in-water emulsion selected from the group consisting of Lipofundin, Intralipid, Lipovenoes, Abbolipid, Deltalipid and Salvilipid.

39. (currently amended) Dispersion according to claim 42, wherein the active ingredient is selected from the group consisting of medical drugs for treatment of human or animal bodies.

40. (currently amended) Dispersion according to claim 42, wherein the dispersion contains one or more active ingredients selected from the group consisting of anaesthetics, antibiotics, antimycotics, antinfectives, corticoids, hormones, antiestrogens antiseptics, vasoactivating agents, glauco agents, beta

Application No. 09/915,549
November 28, 2005
Page 8 of 14

blocker, cholinergics, sympathomimetics, carboanhydrase inhibitors, mydriatics, virustatics, agents for tumor therapy, antiallergics, vitamins, antiinflammatory drugs, immuno-suppressives, ciclosporine, and any combination thereof.

41. (currently amended) Dispersion according to claim 42, wherein the dispersion is positively charged.

42. (currently amended) Dispersion according to claim 42, wherein the dispersion comprises at least one positively charged stabilizer.

43. (currently amended) Dispersion according to claim 42, wherein the dispersion comprises at least one positively charged stabilizer selected from the group consisting of sodium lauryl sulfate, stearylamine, positively charged phospholipids, and positively charged lipids.

44. (currently amended) Dispersion according to claim 42, wherein the dispersion comprises an oil-in-water emulsion adapted for intravenous injection, and wherein the dispersion comprises at least one positively charged stabilizer.

45. (original) Dispersion according to claim 44, wherein the dispersion further includes at least one lecithines or nonionic stabilizers.

46. (original) Dispersion according to claim 44, wherein the dispersion further comprises at least one poloxamer polymer.

47. (currently amended) Dispersion according to claim 42, wherein the active ingredient comprises ciclosporine.

48. (currently amended) Dispersion according to claim 42, wherein the active ingredient comprises at least one selected from the group consisting of anti-mycotics, Amphotericin B, anti-infectives, Buparvaquone, Atovaquone, immuno-

Application No. 09/915,549
November 28, 2005
Page 9 of 14

suppressives, Cyclosporin A, natural and synthetic derivatives of Cyclosporin A, tumor therapy drugs, Paclitaxel, and Taxotere.

49. (currently amended) Dispersion according to claim 42, wherein the active ingredient has a solubility of less than 1 part per 100 parts in the aqueous phase.

50. (currently amended) Dispersion according to claim 42, wherein the active ingredient has a solubility of less than 1 part per 1000 parts in the aqueous phase.

51. (currently amended) Dispersion according to claim 42, wherein the active ingredient has a solubility of less than 1 part per 10,000 parts in the aqueous phase.

52. (currently amended) Dispersion according to claim 42, wherein the active ingredient has a solubility of less than 1 part per 100 parts in the oily phase.

53. (currently amended) Dispersion according to claim 42, wherein the active ingredient has a solubility of less than 1 part per 1000 parts in the oily phase.

54. (currently amended) Dispersion according to claim 42, wherein the active ingredient has a solubility of less than 1 part per 10,000 parts in the oily phase.

55. (currently amended) Dispersion according to claim 42, wherein the size of water phase and oily phase droplets is less than about 10 μm .

56. (currently amended) Dispersion according to claim 42, wherein the size of water phase and oily phase droplets is less than about 5 μm .

57. (currently amended) Dispersion according to claim 42, wherein the size of water phase and oily phase droplets is less than about 1 μm .

Application No. 09/915,549
November 28, 2005
Page 10 of 14

58. (currently amended) Dispersion according to claim 42, wherein a pH of the dispersion is between 4 and 8.

59. (currently amended) Dispersion according to claim 42, wherein a pH of the dispersion is between 5 and 7.5.

60. (currently amended) Dispersion according to claim 42, wherein a pH of the dispersion is between 6 and 7.5.

61. (currently amended) Dispersion according to claim 42, wherein the active ingredient is present in an amount of from about 0.01 to about 30 wt.%, based on the total weight of the dispersion.

62. (currently amended) Dispersion according to claim 42, wherein the active ingredient is present in an amount of from about 0.1 to about 10 wt.%, based on the total weight of the dispersion.

63. (currently amended) Dispersion according to claim 42, wherein the active ingredient is present in an amount of from about 1 to about 5 wt.%, based on the total weight of the dispersion.

64. (currently amended) Dispersion according to claim 42, wherein the quantity of active ingredient dissolved is greater than the additive quantity by a factor of 2.

65. (currently amended) Dispersion according to claim 42, wherein the quantity of active ingredient dissolved is greater than the additive quantity by a factor of 5.

Application No. 09/915,549
November 28, 2005
Page 11 of 14

66. (currently amended) Dispersion according to claim 42, wherein the quantity of active ingredient dissolved is greater than the additive quantity by a factor of 10.

67. (currently amended) A medicament comprising the dispersion according to claim 4 2.

68. (currently amended) A medicament for treatment of mycoses, inflammations, allergic diseases, tumor diseases, cardiovascular diseases, viral and other infections, or for conducting anaesthetic treatment comprising a dispersion according to claim 42.

Claims 67-142 (canceled)

143. (currently amended) A medicament which can be administered intravenously, intra- and subcutaneously, intramuscularly, intra-articularly or intraperitoneally comprising a dispersion according to claim 42.

144. (currently amended) A medicament which has a prolonged residence time in the blood, compared to negatively charged dispersions, comprising a dispersion according to claim 42.

145. (withdrawn) A medicament which can be administered topically, orally, perorally and parenterally comprising a dispersion according to claim 1.

146. (currently amended) A medicament which can be administered intravenously, intra- and subcutaneously, intramuscularly, intra-articularly or intraperitoneally comprising a dispersion according to claim 42.

147. (withdrawn) A medicament which can be administered to the eye comprising a dispersion according to claim 1.

Application No. 09/915,549
November 28, 2005
Page 12 of 14

148. (currently amended) A medicament which has a prolonged residence time in the blood, compared to negatively charged dispersions, comprising a dispersion according to claim 42.

149. (currently amended) Dispersions in form of an oil-in-water emulsion comprising:

an oil phase;

a water phase;

one or more surfactants or stabilizers; and

one or more drugs being only slightly or poorly soluble in the water and in the oil, the dispersions are supersaturated and contain an incorporated amount of the drug in dispersion that is higher than the additive solubility calculated from the drug solubility in the oil and water phases of the dispersion, and the dispersions are organic solvent-free, wherein the drug, in addition to the dissolved state, is partially present in highly dispersed solid crystalline form, resulting in a dispersion with a heterogeneously dispersed phase of oil drops and active ingredient crystals.

150. (previously presented) Dispersions according to claim 149, wherein the concentration of surfactant, stabilizer or mixtures of surfactants and stabilizers is between 0.1% and 20% by weight.